202220212020201920182017201620152014 August 10, 2022 Summary ToggleSpero Therapeutics Announces Second Quarter 2022 Operating Results and Provides Business Update August 09, 2022 Summary ToggleSpero Therapeutics to Provide Business Update and Report Second Quarter 2022 Financial Results on Wednesday, August 10, 2022 June 27, 2022 Summary ToggleSpero Therapeutics Receives Complete Response Letter from U.S. Food and Drug Administration for Tebipenem HBr New Drug Application May 16, 2022 Summary ToggleSpero Therapeutics Announces First Quarter 2022 Operating Results and Provides Business Update May 11, 2022 Summary ToggleSpero Therapeutics to Present at Upcoming Investor Conferences May 09, 2022 Summary ToggleSpero Therapeutics to Provide Business Update and Report First Quarter 2022 Financial Results on Monday, May 16, 2022 May 03, 2022 Summary ToggleSpero Therapeutics Announces New Strategic Direction Focusing on Advancing Promising Clinical-Stage Pipeline April 21, 2022 Summary ToggleSpero Therapeutics to Present Data at the 32nd European Congress of Clinical Microbiology and Infectious Diseases April 06, 2022 Summary ToggleSpero Therapeutics Tebipenem Pivoxil Hydrobromide Phase 3 Data Published in The New England Journal of Medicine March 31, 2022 Summary ToggleSpero Therapeutics Announces Fourth Quarter and Full Year 2021 Operating Results and Provides Business Update Pagination Current page 1 Page 2 Page 3 Page 4 … Next page Next Last page Last
